Factors affecting operational tolerance after pediatric living-donor liver transplantation: Impact of early post-transplant events and HLA match

Transplant International

Volumn 25, Issue 1, 2012, Pages 97-106

  Ohe, Hidenori ^a   Waki, Kayo ^b   Yoshitomi, Mami ^a   Morimoto, Takeshi ^a   Nafady Hego, Hanaa ^a,c   Satoda, Naoki ^a   Li, Ying ^a   Zhao, Xiangdong ^a   Sakaguchi, Shimon ^d   Uemoto, Shinji ^a   Bishop, G Alex ^e   Koshiba, Takaaki ^f  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Assiut University Faculty of Medicine   (Egypt)

^d OSAKA UNIVERSITY   (Japan)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f KOBE UNIVERSITY   (Japan)

Author keywords

HLA; living donor liver transplantation; operational tolerance; pediatric

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN A; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ALPHA; TACROLIMUS;

ARTICLE; CHILD; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

CELL SEPARATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; PARENTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 83955163645     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01389.x     Document Type: Article

References (47)

1. Ueda M, Oike F, Ogura Y, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl 2006; 12: 1326.
2. Jonas S, Neuhaus R, Junge G, et al. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int Immunopharmacol 2005; 5: 125.
3. Matthews J, Ramos E, Bluestone J,. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003; 3: 794.
4. Tisone G, Orlando G, Angelico M,. Operational tolerance in clinical liver transplantation: emerging developments. Transpl Immunol 2007; 17: 108.
5. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
6. Auchincloss HJ,. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001; 1: 6.
7. Cuturi M, Josien R, Douillard P, et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the alpha 1 helix of the first domain of HLA-B7 01. Transplantation 1995; 59: 661.
8. Gianello P, Fishbein J, Sachs D,. Tolerance to primarily vascularized allografts in miniature swine. Immunol Rev 1993; 133: 19.
9. Knechtle S,. Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 2000; 12: 552.
10. Levisetti M, Padrid P, Szot G, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
11. Remuzzi G, Rossini M, Imberti O, Perico N,. Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet 1991; 337: 750.
12. Sablinski T, Hancock W, Tilney N, Kupiec-Weglinski J,. CD4 monoclonal antibodies in organ transplantation-a review of progress. Transplantation 1991; 52: 579.
13. Subbotin V, Sun H, Aitouche A, et al. Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation 1997; 64: 690.
14. Starzl T, Demetris A, Trucco M, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272.
15. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449.
16. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17: 94.
17. Cortesini R,. Tolerance in clinical liver transplantation. Transpl Immunol 2007; 17: 81.
18. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
19. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86: 1837.
20. Yoshizawa A, Ito A, Li Y, et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 2005; 37: 37.
21. Nafady-Hego H, Li Y, Ohe H, et al. The generation of donor-specific CD4+CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric living-donor liver transplantation. Transplantation 2010; 90: 1547.
22. Dausset J, Hors J, Busson M, et al. Serologically defined HL-A antigens and long-term survival of cadaver kidney transplants. A joint analysis of 918 cases performed by France-Transplant and the London Transplant Group. N Engl J Med 1974; 290: 979.
23. Persijn G, Cohen B, Lansbergen Q, et al. Effect of HLA-A and HLA-B matching on survival of grafts and recipients after renal transplantation. N Engl J Med 1982; 307: 905.
24. Opelz G,. Importance of HLA antigen splits for kidney transplant matching. Lancet 1988; 2: 61.
25. Opelz G,. The benefit of exchanging donor kidneys among transplant centers. N Engl J Med 1988; 318: 1289.
26. Neumann U, Guckelberger O, Langrehr J, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation 2003; 75: 132.
27. Navarro V, Herrine S, Katopes C, Colombe B, Spain C,. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl 2006; 12: 652.
28. Sieders E, Hepkema B, Peeters P, et al. The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation. Liver Transpl 2005; 11: 1541.
29. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
30. Tryphonopoulos P, Ruiz P, Weppler D, et al. Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation 2010; 90: 1536.
31. Ohe H, Li Y, Nafady-Hego H, et al. Minimal but essential doses of immunosuppression: a more realistic approach to improve long-term outcomes for pediatric living-donor liver transplantation. Transplantation 2011; 91: 808.
32. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87: 606.
33. Tanaka K, Uemoto S, Tokunaga Y, et al. Surgical techniques and innovations in living related liver transplantation. Ann Surg 1993; 217: 82.
34. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702.
35. Undre N, Moller A,. Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. Transplant Int 1994; 7 (Suppl 1): S15.
36. Kasahara M, Kiuchi T, Uryuhara K, et al. Role of HLA compatibility in pediatric living-related liver transplantation. Transplantation 2002; 74: 1175.
37. Burns JP,. Research in children. Crit Care Med 2003; 31 (3 Suppl): S131.
38. Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transplant 2008; 14: 1582.
39. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
40. Roelen DL, van Bree SP, van Beelen E, Schanz U, van Rood JJ, Claas FH,. Cytotoxic T lymphocytes against HLA-B antigens are less naive than cytotoxic T lymphocytes against HLA-A antigens. Transplantation 1994; 57: 446.
41. Zhang L, van Bree S, van Rood JJ, Claas FH,. The effect of individual HLA-A and -B mismatches on the generation of cytotoxic T lymphocyte precursors. Transplantation 1990; 50: 1008.
42. Ober C, Hyslop T, Elias S, Weitkamp L, Hauck W,. Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study. Hum Reprod 1998; 13: 33.
43. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
44. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
45. Zinkernagel RM, Doherty PC,. H-2 compatibility requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D. J Exp Med 1975; 141: 1427.
46. Karre K, Ljunggren HG, Piontek G, Kiessling R,. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675.
47. Kamada N,. The immunology of experimental liver transplantation in the rat. Immunology 1985; 55: 369.